Trials / Completed
CompletedNCT02226146
Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid
An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, proof-of-concept, single group study in adult participants with newly diagnosed, moderate to extensive BP.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Bertilimumab |
Timeline
- Start date
- 2016-02-29
- Primary completion
- 2018-04-30
- Completion
- 2018-04-30
- First posted
- 2014-08-27
- Last updated
- 2025-11-26
- Results posted
- 2025-11-26
Locations
8 sites across 2 countries: United States, Israel
Source: ClinicalTrials.gov record NCT02226146. Inclusion in this directory is not an endorsement.